The purpose of this study is to find the optimal doses of two investigational drugs when given in combination in patients with locally advanced or metastatic solid tumors that continue to grow despite prior therapy. The drugs are MPDL3280A and cobimetinib.
MPDL3280A is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. MPDL3280A is given intravenously (by vein).
Cobimetinib works by inhibiting MEK, a protein which fuels cancer growth. It is taken orally (by mouth).